Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

Na Cui; Yonghao Feng; Ming Wang; Xiuyan Lu; Yongmei Huang; Yinghui Chen; Xiaohong Shi

doi:10.1507/endocrj.EJ23-0359

ORIGINAL

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

Na Cui ^†, Yonghao Feng ^†, Ming Wang, Xiuyan Lu, Yongmei Huang, Yinghui Chen , Xiaohong Shi

Author information

Na Cui ^†
Department of Endocrinology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Yonghao Feng ^†
Department of Endocrinology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Ming Wang
Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Xiuyan Lu
Department of Endocrinology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Yongmei Huang
Department of Electromyography, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Yinghui Chen Corresponding author
Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Xiaohong Shi Corresponding author
Department of Endocrinology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Author contributions

†These authors contributed equally: Na Cui, Yonghao Feng

Keywords: Diabetic peripheral neuropathy, Alirocumab, Sciatic nerve, Oxidative stress, Inflammatory response

JOURNAL OPEN ACCESS FULL-TEXT HTML

2024 Volume 71 Issue 3 Pages 233-244

DOI https://doi.org/10.1507/endocrj.EJ23-0359

Browse “Advance online publication” version

Details

Abstract

Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use. The role of PCSK9 in diabetic peripheral neuropathy is still unclear. In this study, the effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve in rats with diabetic peripheral neuropathy and its underlying mechanisms were investigated. The diabetic peripheral neuropathy rat model was established by using a high-fat diet combined with streptozotocin injection, and experimental subjects were divided into normal, diabetic peripheral neuropathy, and alirocumab groups. The results showed that Alirocumab improved nerve conduction, morphological changes, and small fiber deficits in rats with DPN, possibly related to its amelioration of oxidative stress and the inflammatory response.

Corresponding author

Register with J-STAGE for free!